Evidence map›Paper›PMID 41302317›Full record

ArticleHealthcare (Basel, Switzerland)2025

Preliminary Cost-Effectiveness of Re-Purposing β-Blockers as an Adjunct Treatment for Women with Triple-Negative Breast Cancer.

Melanie Lloyd, Erica K Sloan, Clara Marquina, Janet Bouttell, Omar Hassanien, Edoardo Botteri, Zanfina Ademi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Healthcare (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Melanie LloydHealth Economics and Policy Evaluation Group, Centre for Medicine Use and Safety, Monash University, Parkville 3052, Australia.
Erica K SloanMonash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville 3052, Australia.
Clara MarquinaHealth Economics and Policy Evaluation Group, Centre for Medicine Use and Safety, Monash University, Parkville 3052, Australia.
Janet BouttellNottingham University Hospitals NHS Trust, Nottingham NG5 1PB, UK.
Omar HassanienMonash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville 3052, Australia.
Edoardo BotteriDepartment of Research, Cancer Registry of Norway, 0379 Oslo, Norway.
Zanfina AdemiHealth Economics and Policy Evaluation Group, Centre for Medicine Use and Safety, Monash University, Parkville 3052, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

breast cancerdrug repurposinghealth technology assessment

Identifiers

PMID41302317
PMCPMC12652519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.